Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05598827
Other study ID # ZZUSC-15
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date December 28, 2024
Est. completion date December 31, 2025

Study information

Verified date November 2023
Source Henan Cancer Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A total of 90 patients with bone and soft tissue malignancies who planned to receive chemotherapy were enrolled in this study in Henan Cancer Hospital. They were divided into experimental group and control group for anxiety and depression value 24 hours before chemotherapy, anxiety and depression value on the day of chemotherapy, anxiety value and depression value 24 hours after chemotherapy. To evaluate the effects of watching Tik Tok on perichemotherapy anxiety and depression in patients with bone and soft tissue malignant tumors who were to receive chemotherapy, and to evaluate the effects of watching Tik Tok on the incidence of chemotherapy-related complications in patients with bone and soft tissue malignant tumors who were to receive chemotherapy.


Description:

A total of 90 patients with bone and soft tissue malignancies who were scheduled to receive chemotherapy were enrolled in this study in Henan Cancer Hospital. They were divided into experimental group and control group: experimental group: Patients enrolled in this study were encouraged to watch Tik Tok without limit from 24 hours before chemotherapy to the seventh day after chemotherapy. Control group: Viewing Tik Tok was forbidden from 24 hours before chemotherapy to the seventh day after chemotherapy. Anxiety and depression 24 hours before chemotherapy, anxiety and depression 24 hours after chemotherapy, and anxiety and depression 24 hours after chemotherapy. To evaluate the effects of watching Tik Tok on perichemotherapy anxiety and depression in patients with bone and soft tissue malignant tumors who were to receive chemotherapy, and to evaluate the effects of watching Douyin on the incidence of chemotherapy-related complications in patients with bone and soft tissue malignant tumors who were to receive chemotherapy.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 90
Est. completion date December 31, 2025
Est. primary completion date December 31, 2025
Accepts healthy volunteers No
Gender All
Age group 10 Years to 70 Years
Eligibility Inclusion Criteria: Men and women aged 10-70. The Eastern Collaborative Oncology Group (ECOG) physical status score was 0-1. Subjects with amputation can be relaxed up to 2 points. Pathological diagnosis of bone and soft tissue malignancy. Patients who have received at least one previous chemotherapy and are planning to receive new chemotherapy. All acute toxicities from previous antitumor therapy or surgery resolved to grade 0-1 (according to NCI-CTCAE, version 4.03) or to enrollment/exclusion criteria by day 1 of the first cycle (C1D1), with the exception of toxicities such as hair loss that the investigator considered to pose no safety risk to the subject). Adequate organ and bone marrow function, as defined below: Blood routine (no blood transfusion, no G-CSF, no medication correction within 7 days before screening) : Neutrophil count (ANC)=1,500/mm3(1.5×109/L); Platelet count (PLT)=100,000/mm3(100×109/L); Hemoglobin (Hb)=9g/dL(90g/L); Blood biochemical: Serum creatinine (Cr)=1.5× upper limit of normal (ULN) or creatinine clearance (Cockroft-Gault formula)=60ml/min; Total bilirubin (TBIL)=1.5×ULN; Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels =2.5×ULN, and subjects with liver metastases should =5×ULN; Blood coagulation function: International normalized ratio (INR)=1.5, prothrombin time (PT) and activated partial thromboplastin time (APTT)=1.5×ULN; With my consent and signed informed consent, I am willing and able to comply with the planned visit, study treatment, laboratory tests and other test procedures. Exclusion Criteria: Received the following treatment within 7 days before C1D1: Radiotherapy, chemotherapy, immune or molecularly targeted therapy for tumors. Some other investigational drugs. Surgery for other sites and/or radiotherapy were planned during the study period (24 hours before chemotherapy and 7 days after chemotherapy). Imaging diagnosis showed the presence of central nervous system tumor lesions. The presence of active heart disease in the 6 months before C1D1, including myocardial infarction, severe/unstable angina pectoris, etc. Poorly controlled arrhythmias with left ventricular ejection fraction <50% on echocardiography (including QTcF interval >450ms in men and >470ms in women). In the judgment of the investigator, there are concomitant diseases (such as severe diabetes, neurological or psychiatric diseases) or any other conditions that seriously endanger the safety of the subjects, may confuse the results of the study, or affect the completion of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Tik Tok
The enrolled patients were encouraged to watch Tik Tok without limit starting 24 days before chemotherapy and continuing until the seventh day after chemotherapy.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Henan Cancer Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Anxiety and depression Hospital Anxiety Depression Scale 24 hours before chemotherapy
Primary Anxiety and depression Hospital Anxiety Depression Scale 1 day of chemotherapy
Primary Anxiety and depression Hospital Anxiety Depression Scale 24 hours after chemotherapy
See also
  Status Clinical Trial Phase
Completed NCT03652727 - FX vs. ECG Guidance for PICC Insertion N/A
Not yet recruiting NCT05856656 - Music Therapy as a Tool for Anxiety Reduction in Localized Breast Cancer N/A
Active, not recruiting NCT02959541 - PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer N/A
Completed NCT00757094 - Safety and Feasibility of Fasting While Receiving Chemotherapy N/A
Recruiting NCT00797238 - DNA Repair Genes and Outcomes in Patients With Stage III NSCLC N/A
Not yet recruiting NCT05927857 - Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer . Phase 1/Phase 2
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Completed NCT04466332 - Comparison of Two ECG Guided PICC Insertion Techniques N/A
Not yet recruiting NCT04055038 - Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC) Phase 2/Phase 3
Recruiting NCT03701607 - Effect of Chemotherapy on PD-L1 in NSCLC
Recruiting NCT04024241 - Medium Dose of Cytarabine and Mitoxantrone
Recruiting NCT06208436 - The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer
Recruiting NCT05306301 - Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients Phase 2
Active, not recruiting NCT02304640 - Prevalence, Severity and Determinants of Cancer-related Fatigue (CRF) in Asian Breast Cancer Patients
Completed NCT02298972 - Symptom Support During Chemotherapy: A Mixed Method Study in Adult Patients With Cancer N/A
Terminated NCT01249001 - Relative Bioavailability of an Extemporaneous Oral Suspension of Aprepitant in Adolescents Phase 2
Recruiting NCT03089892 - A Perspective Study of Cancer-related Fatigue in Gynecologic Cancer Patients Under Chemotherapy N/A
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Recruiting NCT04472403 - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Terminated NCT02982694 - Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer Phase 2